Valuation: Becton, Dickinson and Company

Market Cap 49.11B 884B 43.88B 40.94B 37.19B 70.04B 4,751B 70.56B 492B 192B 2,416B 184B 180B 7,767B P/E 2026 *
34.7x
P/E 2027 * 19.4x
Enterprise Value 65B 1,171B 58.07B 54.18B 49.21B 92.69B 6,287B 93.38B 651B 254B 3,198B 244B 239B 10,279B EV / Sales 2026 *
3.37x
EV / Sales 2027 * 3.19x
Free-Float
73.18%
Yield 2026 *
2.18%
Yield 2027 * 2.21%
1 day+4.31%
6 months-4.15%
Current year-24.08%
Current year 2,498.49
Extreme 2498.49
3,093.03
1 year 2,498.49
Extreme 2498.49
3,535.21
3 years 2,498.49
Extreme 2498.49
4,843.41
5 years 2,498.49
Extreme 2498.49
5,784.37
10 years 2,498.49
Extreme 2498.49
6,405.1
Manager TitleAgeSince
Chief Executive Officer 53 2020-01-27
Director of Finance/CFO 44 2025-12-04
Chief Tech/Sci/R&D Officer 56 2023-12-03
Director TitleAgeSince
Director/Board Member 75 2002-09-23
Director/Board Member 71 2010-07-25
Chairman 53 2021-04-27
Change 5-day change 1-year change 3-year change Capi.($)
+4.31%-.--% - - 49.11B
+0.42%-0.07%-25.76%+2.07% 170B
-1.75%-0.68%-12.84%+14.07% 111B
-0.91%+0.51%-25.04%+3.74% 107B
-0.03%+0.72%-46.94%-10.20% 75.95B
+0.12%+5.80%+2.90%+70.62% 60.37B
-0.65%+6.59%+11.44%+66.40% 53.53B
-0.61%+0.98%-6.11%-31.99% 49.11B
-2.06%-2.78%-19.07%+14.79% 40.6B
+0.65%-2.13%+27.90%+1.64% 31.47B
Average +0.03%+0.25%-10.39%+14.57% 77.67B
Weighted average by Cap. -0.10%-0.04%-16.38%+12.08%

Financials

2026 *2027 *
Net sales 19.28B 347B 17.22B 16.07B 14.6B 27.49B 1,865B 27.69B 193B 75.44B 948B 72.37B 70.8B 3,049B 19.74B 355B 17.64B 16.45B 14.95B 28.15B 1,909B 28.36B 198B 77.25B 971B 74.1B 72.5B 3,122B
Net income 1.44B 25.87B 1.28B 1.2B 1.09B 2.05B 139B 2.06B 14.39B 5.62B 70.68B 5.39B 5.28B 227B 2.34B 42.13B 2.09B 1.95B 1.77B 3.34B 226B 3.36B 23.44B 9.16B 115B 8.78B 8.59B 370B
Net Debt 15.88B 286B 14.19B 13.24B 12.03B 22.65B 1,537B 22.82B 159B 62.17B 781B 59.63B 58.35B 2,512B 13.95B 251B 12.47B 11.63B 10.56B 19.9B 1,350B 20.04B 140B 54.6B 686B 52.38B 51.24B 2,207B
Projected Income Statement - Annual - Becton, Dickinson and Company
Logo Becton, Dickinson and Company
Becton, Dickinson and Company specializes in the development, manufacturing and marketing of medical and diagnostic equipment and materials. Net sales break down by family of products as follows: - medical management systems (52.4%): medication delivery systems, pharmaceutical systems, advanced patient monitoring systems, etc.; - interventional medical equipment (23.9%): surgical instruments, urological care products, etc.; - diagnostic materials and clinical research and development tools (23.7%): automated systems for blood testing, mycobacteria detection, and molecular biology, medical biology devices, tools for studying genes and culturing cells, instruments for sorting and analyzing cells, monoclonal antibodies, etc. Net sales are distributed geographically as follows: the United States (58.6%), Europe/Middle East/Africa (21.6%), Asia (14.2%) and other (5.6%).
Employees
72,000
Trader
Investor
Global
Quality
ESG MSCI
A
Ratings Surperformance© - Becton, Dickinson and Company
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
15
Last Close Price
180.30USD
Average target price
194.08USD
Spread / Average Target
+7.64%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Becton, Dickinson and Company